Contact Us To Participate or Learn More:If you wish tolearn moreabout this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.Charles Linehan, Esq.,Glancy Prongay & Murray LLP,1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected]Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at www.glancylaw.com.Follow us for updates on LinkedIn, Twitter, or Facebook. If yo ...

Accessibility StatementSkip Navigation LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Sable Offshore Corp. ("Sable" or the "Company") (NYSE:Â SOC). IF YOU SUFFERED A LOSS ON YOUR SABLE INVESTMENTS, CLICKÂ HERE BEFORE SEPTEMBER 26, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, betwe ...

Accessibility StatementSkip Navigation 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED Also from this source If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some ...

Core Viewpoint - Investors in Fly-E Group, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements made by the company's defendants regarding its business operations and market conditions [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from July 15, 2025, to August 14, 2025, the defendants failed to disclose critical information about Fly-E's brand reputation, cost reductions, and supplier pricing, which were presented as key factors for the company's sales growth [2]. - It is alleged that the defendants minimized risks related to lithium battery issues, supply chain changes, regulatory challenges, and demand fluctuations for Fly-E's E-Bikes and E-Scooters [2]. - The positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses in Fly-E are encouraged to participate in the ongoing lawsuit before the lead plaintiff deadline of November 7, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding the lawsuit [3][4].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of CarMax, Inc. ("CarMax†or the "Company†) (NYSE: KMX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CARMAX, INC. (KMX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On April 10, 2025, CarMax released its fourth quarter and fiscal year 2025 financia. ...

Core Viewpoint - Novo Nordisk A/S is facing a class action lawsuit due to a significant reduction in its fiscal year 2025 guidance, which has led to a substantial drop in its stock price and alleged misleading statements made by the company during the class period [2][3][4]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk revised its fiscal year 2025 guidance, lowering sales growth expectations from 13-21% to 8-14% and operating profit from 16-24% to 10-16% [2]. - The company cited lower growth expectations for its products Ozempic and Wegovy, attributing this to market expansion slowdowns, increased competition, and ongoing use of compounded GLP-1s [2]. Group 2: Stock Impact - Following the announcement of the revised guidance, Novo Nordisk's stock price fell by $15.06, or 21.8%, closing at $53.94 per share on July 29, 2025 [3]. Group 3: Legal Action - The class action lawsuit alleges that during the class period, Novo Nordisk made materially false and misleading statements and failed to disclose adverse facts about its business and prospects [4]. - Specific allegations include the company's failure to recognize the significance of the personalization exception for GLP-1 compounding and overestimating its ability to attract patients transitioning from compounded treatments [4]. - Investors who purchased Novo Nordisk securities during the class period have until September 30, 2025, to file a lead plaintiff motion in the lawsuit [5].

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SELECTQUOTE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAI ...

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIAL ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of federal securities laws during the defined class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Jasper securities between November 30, 2023, and July 3, 2025 [2]. Case Details - The Complaint alleges that Jasper made materially false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - Heightened likelihood of disruptive cost-reduction measures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Defendants' statements regarding the Company's operations and prospects were materially false and misleading [3]. Next Steps - Interested parties can review the Complaint and have until November 18, 2025, to request appointment as lead plaintiff [4]. Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].